Journal of Chemistry · 2009 · 14 citations · 3 references
PharmacyPharmacokineticsPharmacologyBioavailabilityClinical PharmacologyMass Spectrometric AnalysisBioanalytical Method ValidationBioavailability AnalysisChromatographyDrug DispositionLiquid ChromatographyMass SpectrometryLiquid Chromatography-mass SpectrometryLiquid Chromatography-mass Spectrometry AnalysisMass Spectrometric Drug AnalysisMass Spectrometric QuantificationMemantine PharmacokineticsOral Drug BioavailabilityRegulatory Acceptance CriteriaUltra-performance Liquid Chromatography-mass Spectrometry
The aim of this study is to compare the single‐dose oral bioavailability of memantine hydrochloride 10 mg tablets of Ranbaxy Laboratories Limited, with NAMENDA™ tablets (containing memantine hydrochloride 10 mg) of Forest Pharmaceuticals Inc. in healthy, adult, human subjects under fasting condition. The study was carried out as 2‐way crossover design on 8 subjects in fasting and fed conditions. The plasma samples were obtained over a 72 h post dose in each period. Plasma memantine samples were analyzed by liquid chromatography coupled to tandem mass spectrometry (LC‐MS/MS) with positive ion electro spray ionization using multiple reactions monitoring (MRM). A sensitive, reproducible, accurate and validated LC‐MS/MS method with limit of quantification (LOQ) 0.200 ng/mL was used to analyze memantine. Ln transformed AUC 0-72 and C max were assessed for bioequivalence using 90% confidence interval (CI). 90% confidence intervals for the ratio of test and reference (Ratio of least‐squares mean) for ln‐transformed AUC 0-72 and C max were within the regulatory acceptance criteria of 80‐125%.
3